SOFDRA Drug Patent Profile
When do Sofdra patents expire, and when can generic versions of Sofdra launch?
Sofdra is a drug marketed by Botanix Sb and is included in one NDA. There are twenty-one patents protecting this drug.
The generic ingredient in SOFDRA is sofpironium bromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the sofpironium bromide profile page.
DrugPatentWatch® Generic Entry Outlook for Sofdra
Sofdra will be eligible for patent challenges on June 20, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 22, 2040. This may change due to patent challenges or generic licensing.
There have been eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SOFDRA?
- What are the global sales for SOFDRA?
- What is Average Wholesale Price for SOFDRA?
Summary for SOFDRA
| US Patents: | 21 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 33 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SOFDRA |
| What excipients (inactive ingredients) are in SOFDRA? | SOFDRA excipients list |
| DailyMed Link: | SOFDRA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SOFDRA
Generic Entry Date for SOFDRA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
GEL, METERED;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for SOFDRA
SOFDRA is protected by twenty-one US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SOFDRA is ⤷ Start Trial.
This potential generic entry date is based on patent 12,703,682.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Botanix Sb | SOFDRA | sofpironium bromide | GEL, METERED;TOPICAL | 217347-001 | Jun 18, 2024 | RX | Yes | Yes | 12,357,609 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Botanix Sb | SOFDRA | sofpironium bromide | GEL, METERED;TOPICAL | 217347-001 | Jun 18, 2024 | RX | Yes | Yes | 8,147,809 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Botanix Sb | SOFDRA | sofpironium bromide | GEL, METERED;TOPICAL | 217347-001 | Jun 18, 2024 | RX | Yes | Yes | 11,034,652 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Botanix Sb | SOFDRA | sofpironium bromide | GEL, METERED;TOPICAL | 217347-001 | Jun 18, 2024 | RX | Yes | Yes | 11,123,325 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Botanix Sb | SOFDRA | sofpironium bromide | GEL, METERED;TOPICAL | 217347-001 | Jun 18, 2024 | RX | Yes | Yes | 10,952,990 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Botanix Sb | SOFDRA | sofpironium bromide | GEL, METERED;TOPICAL | 217347-001 | Jun 18, 2024 | RX | Yes | Yes | 11,584,715 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Botanix Sb | SOFDRA | sofpironium bromide | GEL, METERED;TOPICAL | 217347-001 | Jun 18, 2024 | RX | Yes | Yes | 11,026,919 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SOFDRA
When does loss-of-exclusivity occur for SOFDRA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 20277881
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 2021023241
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 39948
Estimated Expiration: ⤷ Start Trial
Chile
Patent: 21003047
Estimated Expiration: ⤷ Start Trial
China
Patent: 4008023
Estimated Expiration: ⤷ Start Trial
Colombia
Patent: 21017456
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 72955
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 8285
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 48329
Estimated Expiration: ⤷ Start Trial
Patent: 05598
Estimated Expiration: ⤷ Start Trial
Patent: 20189839
Estimated Expiration: ⤷ Start Trial
Patent: 20189856
Estimated Expiration: ⤷ Start Trial
Malaysia
Patent: 6154
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 21014163
Estimated Expiration: ⤷ Start Trial
Philippines
Patent: 021552915
Estimated Expiration: ⤷ Start Trial
Singapore
Patent: 202111678W
Estimated Expiration: ⤷ Start Trial
South Africa
Patent: 2109514
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 220011671
Estimated Expiration: ⤷ Start Trial
Patent: 260110270
Estimated Expiration: ⤷ Start Trial
Taiwan
Patent: 2110796
Estimated Expiration: ⤷ Start Trial
Patent: 2411205
Estimated Expiration: ⤷ Start Trial
Patent: 38531
Estimated Expiration: ⤷ Start Trial
Patent: 70116
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SOFDRA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2014227923 | ⤷ Start Trial | |
| Brazil | 112015023153 | ⤷ Start Trial | |
| Canada | 2904724 | ⤷ Start Trial | |
| China | 105050596 | ⤷ Start Trial | |
| China | 109364066 | ⤷ Start Trial | |
| Denmark | 2968267 | ⤷ Start Trial | |
| European Patent Office | 2968267 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
SOFDRA market dynamics and financial trajectory: revenue exposure, exclusivity timing, and competitive pressure
More… ↓

